Suppr超能文献

人P2Y受体不同激动剂结合位点及激活机制的鉴定

Identification of a Different Agonist-Binding Site and Activation Mechanism of the Human P2Y Receptor.

作者信息

Li Yang, Yin Can, Liu Pi, Li Dongmei, Lin Jianping

机构信息

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, China.

Pharmaceutical Intelligence Platform, Tianjin Joint Academy of Biomedicine and Technology, Tianjin, 300457, China.

出版信息

Sci Rep. 2017 Oct 23;7(1):13764. doi: 10.1038/s41598-017-14268-1.

Abstract

The human P2Y receptor (P2YR) is a purinergic G-protein-coupled receptor (GPCR) that functions as a receptor for adenosine 5'-diphosphate (ADP). An antagonist of P2YR might potentially have antithrombotic effects, whereas agonists might serve as antidiabetic agents. On the basis of the antagonist-bound MRS2500-P2YR crystal structure, we constructed computational models of apo-P2YR and the agonist-receptor complex 2MeSADP-P2YR. We then performed conventional molecular dynamics (cMD) and accelerated molecular dynamics (aMD) simulations to study the conformational dynamics after binding with agonist/antagonist as well as the P2YR activation mechanism. We identified a new agonist-binding site of P2YR that is consistent with previous mutagenesis data. This new site is deeper than those of the agonist ADP in the recently simulated ADP-P2YR structure and the antagonist MRS2500 in the MRS2500-P2YR crystal structure. During P2YR activation, the cytoplasmic end of helix VI shifts outward 9.1 Å, the Ser146-Tyr237 hydrogen bond breaks, a Tyr237-Val262 hydrogen bond forms, and the conformation of the χ1 rotamer of Phe269 changes from parallel to perpendicular to helix VI. The apo-P2YR system and the MRS2500-P2YR system remain inactive. The newly identified agonist binding site and activation mechanism revealed in this study may aid in the design of P2YR antagonists/agonists as antithrombotic/antidiabetic agents, respectively.

摘要

人类P2Y受体(P2YR)是一种嘌呤能G蛋白偶联受体(GPCR),作为5'-二磷酸腺苷(ADP)的受体发挥作用。P2YR的拮抗剂可能具有抗血栓形成作用,而激动剂可能用作抗糖尿病药物。基于与拮抗剂结合的MRS2500-P2YR晶体结构,我们构建了无配体P2YR和激动剂-受体复合物2MeSADP-P2YR的计算模型。然后,我们进行了传统分子动力学(cMD)和加速分子动力学(aMD)模拟,以研究与激动剂/拮抗剂结合后的构象动力学以及P2YR的激活机制。我们确定了一个新的P2YR激动剂结合位点,该位点与先前的诱变数据一致。这个新位点比最近模拟的ADP-P2YR结构中的激动剂ADP和MRS2500-P2YR晶体结构中的拮抗剂MRS2500的结合位点更深。在P2YR激活过程中,螺旋VI的胞质端向外移动9.1Å,Ser146-Tyr237氢键断裂,Tyr237-Val262氢键形成,Phe269的χ1旋转异构体的构象从与螺旋VI平行变为垂直。无配体P2YR系统和MRS2500-P2YR系统仍处于无活性状态。本研究中揭示的新的激动剂结合位点和激活机制可能分别有助于设计作为抗血栓形成/抗糖尿病药物的P2YR拮抗剂/激动剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad6b/5653743/20f8fd95f10b/41598_2017_14268_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验